Royal Bank of Canada Lowers Stock Holdings in Certara, Inc. $CERT

Royal Bank of Canada lowered its position in shares of Certara, Inc. (NASDAQ:CERT) by 19.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,009,089 shares of the company’s stock after selling 245,200 shares during the period. Royal Bank of Canada’s holdings in Certara were worth $5,752,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of the company. Northwestern Mutual Wealth Management Co. raised its holdings in shares of Certara by 2,733.3% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,975 shares of the company’s stock valued at $26,000 after buying an additional 2,870 shares in the last quarter. Osaic Holdings Inc. boosted its stake in Certara by 50.7% in the second quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock worth $41,000 after buying an additional 1,175 shares in the last quarter. Tower Research Capital LLC TRC grew its position in Certara by 499.5% during the second quarter. Tower Research Capital LLC TRC now owns 5,917 shares of the company’s stock valued at $69,000 after acquiring an additional 4,930 shares during the last quarter. Chicago Partners Investment Group LLC bought a new position in Certara during the first quarter valued at approximately $78,000. Finally, Kera Capital Partners Inc. purchased a new position in shares of Certara during the first quarter worth approximately $80,000. 73.96% of the stock is currently owned by institutional investors.

Certara Stock Down 1.5%

Shares of NASDAQ CERT opened at $8.01 on Thursday. The company has a quick ratio of 2.55, a current ratio of 2.55 and a debt-to-equity ratio of 0.30. Certara, Inc. has a 52 week low of $4.45 and a 52 week high of $13.88. The firm’s fifty day moving average is $6.70 and its 200 day moving average is $6.50. The company has a market cap of $1.22 billion, a price-to-earnings ratio of -17.80 and a beta of 1.44.

Certara (NASDAQ:CERT) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.01). The firm had revenue of $93.27 million for the quarter, compared to analysts’ expectations of $98.09 million. Certara had a negative net margin of 16.75% and a positive return on equity of 3.86%. The company’s quarterly revenue was down 10.8% on a year-over-year basis. During the same period in the previous year, the company earned $0.07 EPS. On average, equities research analysts expect that Certara, Inc. will post 0.22 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. Morgan Stanley lowered their price objective on shares of Certara from $11.00 to $10.00 and set an “equal weight” rating for the company in a report on Tuesday, May 12th. Barclays boosted their price target on shares of Certara from $6.50 to $7.50 and gave the stock an “equal weight” rating in a research note on Wednesday, August 5th. Craig Hallum reduced their price objective on Certara from $10.00 to $8.00 and set a “hold” rating on the stock in a research note on Tuesday, May 12th. Robert W. Baird decreased their price objective on Certara from $7.00 to $6.00 and set a “neutral” rating on the stock in a report on Tuesday, May 12th. Finally, Weiss Ratings raised Certara from a “sell (e+)” rating to a “sell (d)” rating in a research note on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Certara presently has a consensus rating of “Hold” and a consensus target price of $8.28.

Certara Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.